Skip to main content
SUTRO BIOPHARMA, INC. logo

SUTRO BIOPHARMA, INC. — Investor Relations & Filings

Ticker · STRO ISIN · US8693671021 LEI · 5493005U6P15VD25P851 US Manufacturing
Open in API
Filings indexed 586 across all filing types
Latest filing 2020-08-21 Director's Dealing
Country US United States of America
Listing US STRO

About SUTRO BIOPHARMA, INC.

https://www.sutrobio.com/

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of precisely designed cancer therapeutics. The company leverages its proprietary, integrated cell-free protein synthesis platform to create novel antibody-drug conjugates (ADCs). This technology enables the development of next-generation ADCs, including those with single and dual payloads, which are designed to offer improved therapeutic profiles for patients with cancer. Sutro is advancing its own pipeline of clinical-stage product candidates to address areas of significant unmet medical need.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2020-08-21 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 6, 2020, by Sutro Biopharma, Inc. It announces the issuance of a press release regarding financial results for the period ended June 30, 2020. The document explicitly states that the press release is attached as Exhibit 99.1 and that the information is being furnished and not filed, indicating this is an announcement of financial results rather than the full financial report itself. The length of the document is 3490 characters, which is relatively short and consistent with an announcement rather than a full earnings release or quarterly report. The key section is Item 2.02 "Results of Operations and Financial Condition," which typically corresponds to earnings releases or financial results announcements. Given the short length and nature of the document, it fits best as an Earnings Release (ER) announcement rather than a full Interim/Quarterly Report (IR) or Annual Report (10-K).
2020-08-06 English
10-Q
Interim / Quarterly Report Q2 2020
2020-08-06 English
FORM 4 SUBMISSION
Director's Dealing
2020-07-28 English
FORM 4 SUBMISSION
Director's Dealing
2020-06-30 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 15, 2020. It announces that Sutro Biopharma, Inc. intends to present an updated corporate presentation at a conference and attaches the presentation as Exhibit 99.1. The text explicitly states this is a corporate presentation and provides a link to the presentation on the company's website. The document is relatively short (3581 characters) and primarily serves to announce and furnish the presentation rather than being the presentation itself or a detailed financial report. According to the classification rules, such documents announcing or furnishing presentations are best classified as Investor Presentation (IP).
2020-06-15 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.